ETR:SAZ STADA Arzneimittel Aktiengesellschaft Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding STADA Arzneimittel Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. €80.40 0.00 (0.00%) (As of 11/27/2018) Add Compare Share Today's Range€79.56▼€80.9850-Day Range€80.40▼€80.4052-Week Range€53.41▼€80.98Volume92,068 shsAverage Volume51,761 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlines STADA Arzneimittel Aktiengesellschaft MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.22 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for STADA Arzneimittel Aktiengesellschaft. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for SAZ. Previous Next 0.0 Dividend Strength Dividend YieldSTADA Arzneimittel Aktiengesellschaft does not currently pay a dividend.Dividend GrowthSTADA Arzneimittel Aktiengesellschaft does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SAZ. Previous Next 1.1 News and Social Media Coverage News SentimentSTADA Arzneimittel Aktiengesellschaft has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, STADA Arzneimittel Aktiengesellschaft insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address About STADA Arzneimittel Aktiengesellschaft (ETR:SAZ) StockSTADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.Read More SAZ Stock News HeadlinesFebruary 10, 2021 | marketwatch.comGeneric Drugs Market Size Worth Around US$ 675.2 Bn by 2030February 10, 2021 | benzinga.comGlobal Erythropoietin Market Report (2020 to 2030) - COVID-19 Growth and ChangeFebruary 3, 2021 | marketwatch.comGlobal Parkinson's Disease Drug Market 2020 Industry Analysis, Size, Share, Growth, Trend and Forecast to 2025February 2, 2021 | marketwatch.comGlobal Generic Drugs Market : Regional Industry Segmentation, Analysis by Production, Consumption, Revenue and Growth Rate by 2027January 12, 2021 | marketwatch.comBiosimilars Market Size, Key Regions, Development Status, CAGR Value, Total Revenues, Future Outlook, Opportunities and Drivers, Forecast to 2023December 21, 2020 | benzinga.comErythropoietin (EPO) Global Market Report 2020-30: COVID-19 Growth and ChangeDecember 10, 2020 | markets.businessinsider.comSTADA agreement extended for the Nordic RegionDecember 3, 2020 | marketwatch.comGlobal Opipramol Market 2020 Key Players Data, Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2025December 3, 2020 | marketwatch.comGlobal Opipramol Market Size Study with COVID-19 Impact 2020 Research Strategies and Forecast to 2025November 24, 2020 | marketwatch.comGlobal Bio Similars/Subsequent Entry Biologic Market 2020 Key Drivers and Challenges, Opportunities and Forecast Insights by 2026November 11, 2020 | marketwatch.comGlobal Parkinson's Disease Therapeutics Market 2020 Technological Strategies, Business Advancements and Top-Vendor Landscape to 2026November 5, 2020 | marketwatch.comOncology Biosimilars Market 2020 Top Key Players with Business Overview, Share, Size, Types and Applications and Forecast to 2026October 24, 2020 | nasdaq.comStada Arzneimittel AG Registered Shares (STDAF)See More Headlines Industry, Sector and Symbol Stock ExchangeETR Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolETR:SAZ CUSIPN/A CIKN/A Webwww.stada.de Phone+49-6101-6030FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A STADA Arzneimittel Aktiengesellschaft Frequently Asked Questions How has STADA Arzneimittel Aktiengesellschaft's stock performed in 2022? STADA Arzneimittel Aktiengesellschaft's stock was trading at €80.40 on January 1st, 2022. Since then, SAZ stock has increased by 0.0% and is now trading at €80.40. View the best growth stocks for 2022 here. Who are STADA Arzneimittel Aktiengesellschaft's key executives? STADA Arzneimittel Aktiengesellschaft's management team includes the following people: Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 54)Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 53)Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)Ms. Kay Reubelt, Director of Investor Relations Who are some of STADA Arzneimittel Aktiengesellschaft's key competitors? Some companies that are related to STADA Arzneimittel Aktiengesellschaft include Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACGWF), Althea Group (AGH), Applied Biosciences (APPB), AusCann Group (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Cannara Biotech (LOVE), CannPal Animal Therapeutics (CP1), Cansortium (CNTMF), Chalice Brands (GLDFF), Charlotte's Web (CWBHF) and China Auto Logistics (CALI). View all of SAZ's competitors. What other stocks do shareholders of STADA Arzneimittel Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some companies that other STADA Arzneimittel Aktiengesellschaft investors own include ProSiebenSat.1 Media (PSM), Renault (RNO), Sarepta Therapeutics (SRPT), Volkswagen Aktiengesellschaft (VLKAY), Volkswagen (VOW3), ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), Andersons (ANDE) and ANI Pharmaceuticals (ANIP). What is STADA Arzneimittel Aktiengesellschaft's stock symbol? STADA Arzneimittel Aktiengesellschaft trades on the ETR under the ticker symbol "SAZ." What is STADA Arzneimittel Aktiengesellschaft's stock price today? One share of SAZ stock can currently be purchased for approximately €80.40. How can I contact STADA Arzneimittel Aktiengesellschaft? STADA Arzneimittel Aktiengesellschaft's mailing address is Stadastrasse 2-18, BAD VILBEL, 61118, Germany. The official website for STADA Arzneimittel Aktiengesellschaft is www.stada.de. The company can be reached via phone at +49-6101-6030. This page (ETR:SAZ) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
